U.S. Markets open in 4 hrs 35 mins

Have Insiders Been Buying Australian Pharmaceutical Industries Limited (ASX:API) Shares This Year?

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we'll take a look at whether insiders have been buying or selling shares in Australian Pharmaceutical Industries Limited (ASX:API).

Do Insider Transactions Matter?

It's quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, such insiders must disclose their trading activities, and not trade on inside information.

Insider transactions are not the most important thing when it comes to long-term investing. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'

Check out our latest analysis for Australian Pharmaceutical Industries

The Last 12 Months Of Insider Transactions At Australian Pharmaceutical Industries

In the last twelve months, the biggest single purchase by an insider was when Non-Executive Chairman Mark Smith bought AU$107k worth of shares at a price of AU$1.52 per share. That means that an insider was happy to buy shares at above the current price of AU$1.35. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Mark Smith was the only individual insider to buy shares in the last twelve months.

Mark Smith purchased 135k shares over the year. The average price per share was AU$1.44. You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

ASX:API Recent Insider Trading, June 17th 2019

Australian Pharmaceutical Industries is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership of Australian Pharmaceutical Industries

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data indicates that Australian Pharmaceutical Industries insiders own about AU$11m worth of shares (which is 1.6% of the company). Whilst better than nothing, we're not overly impressed by these holdings.

What Might The Insider Transactions At Australian Pharmaceutical Industries Tell Us?

We note a that there has been a bit of insider buying recently (but no selling). That said, the purchases were not large. However, our analysis of transactions over the last year is heartening. Insiders own shares in Australian Pharmaceutical Industries and we see no evidence to suggest they are worried about the future. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Australian Pharmaceutical Industries.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.